文献速递疼痛医学

类固醇枕大神经阻滞治疗丛集性头痛的系统评价与荟萃分析

Therapeutic effectiveness and safety profile of steroid-based greater occipital nerve blocks in cluster headaches: a systematic review and meta-analysis.
PubMed 文献 · Reg Anesth Pain Med · 2025-12-31

颗粒类固醇阻滞后平均疗效持续时间为丛集性头痛43天、发作性61.6天、慢性32.2天,应答概率分别为73%、77%、69%。慢性丛集性头痛发作频率显著降低,不良事件多为轻微短暂。

要点

  • 颗粒类固醇枕大神经阻滞后平均疗效持续时间:丛集性头痛43天,发作性61.6天,慢性32.2天。
  • 应答概率:丛集性头痛73%,发作性77%,慢性69%;敏感性分析结果相似。
  • 慢性丛集性头痛发作频率显著降低(p=0.01,RR=2.67,95%CI 1.24-5.75)。

核心结论

  • 颗粒类固醇枕大神经阻滞可降低丛集性头痛发作频率,不良事件多为短期,证据质量从极低到中等。

主要发现

  • 所有研究均提示颗粒类固醇枕大神经阻滞后结局改善,单次与多次注射疗效相似。
  • 平均疗效持续时间:丛集性头痛43天,发作性61.6天,慢性32.2天。
  • 比例荟萃分析应答概率:丛集性头痛73%,发作性77%,慢性69%(I²分别为86.5%、47.8%、89.9%);敏感性分析:79%、75%、70%。
  • 二分类荟萃分析显示丛集性头痛(p=0.06)和发作性(p=0.11)发作频率降低不显著,慢性显著降低(p=0.01,相对危险度=2.67,95%CI 1.24至5.75)。
  • 不良事件组间无差异(p=0.43)。

临床怎么用

  • 对慢性丛集性头痛患者,可考虑使用颗粒类固醇枕大神经阻滞以降低发作频率。
  • 治疗获益持续时间因头痛类型而异,需根据发作性或慢性形式评估预期效果。

局限性

  • 证据质量从极低到中等。
  • 部分荟萃分析异质性较高(I²最高达89.9%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cluster headaches (CHs), including episodic (ECH) and chronic (CCH) forms, are intensely painful and disabling, with limited preventative options. Greater occipital nerve blocks (GONBs) are frequently used in practice; however, the safety and efficacy of steroid-based injections, alone or combined with local anesthetic in CH patients, remain unclear. OBJECTIVE: To evaluate the efficacy and safety of corticosteroid-based GONBs, with or without local anesthetic, in patients with CHs, including ECH and CCH. Outcomes included attack frequency, proportion of responders, duration of effect, pain reduction, and adverse events. EVIDENCE REVIEW: We systematically searched Cochrane, Embase, Emcare, PubMed, and PsycInfo from inception to March 24, 2025 for eligible studies involving patients with CHs who received GONBs stratified by corticosteroid use. Data were narratively synthesized, with random-effects meta-analyses performed: a proportional meta-analysis of GONB arms, and a binary meta-analysis of randomized studies comparing GONBs versus control (saline±local anesthetic). Subgroup and risk of bias (RoB) sensitivity analyses were conducted for ECH and CCH. RoB was assessed using the Cochrane RoB 2.0 and ROBINS-I tools. Certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation. Protocol registered on OSF (https://doi.org/10.17605/OSF.IO/6EAZN). No funding was received. FINDINGS: Nineteen studies were included, comprising 758 CHs, 324 ECHs, and 375 CCH patients. All studies suggested improvements in outcomes with particulate steroid-based GONBs. Pooled data showed similar efficacy between single and multiple injections, with mostly minor, transient adverse events and consistent reductions in pain across studies. Mean duration of effect was 43 days (CH), 61.6 days (ECH), and 32.2 days (CCH). Proportional meta-analyses explored probabilities of response: CH=73%, ECH=77%, CCH=69% (I²=86.5%, 47.8%, 89.9%). Sensitivity analyses provided similar estimates: CH=79%, ECH=75%, CCH=70%. Binary meta-analyses showed non-significant reductions in attack frequency for CH (p=0.06) and ECH (p=0.11), and a significant reduction for CCH (p=0.01, relative risk=2.67, 95% CI 1.24 to 5.75). Adverse events did not differ between groups (p=0.43). CONCLUSION: Particulate steroid-based GONBs show promise for CH treatment by decreasing attack frequency, while mostly producing short-term adverse events. The evidence quality spans from very low to moderate.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Mustafa AD, Freire de Oliveira L, Espinola Saldanha R, et al. Therapeutic effectiveness and safety profile of steroid-based greater occipital nerve blocks in cluster headaches: a systematic review and meta-analysis. Reg Anesth Pain Med. 2025. PMID: 41475886. doi:10.1136/rapm-2025-106987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。